1,3-Benzodioxolyl-N-ethylbutanamine

EBDB
Clinical data
Other names1,3-Benzodioxolyl-N-ethylbutanamine; EBDB; 3,4-Methenedioxy-α,N-diethylphenethylamine
Routes of
administration		Oral
ATC code
  • None
Pharmacokinetic data
Duration of action"Probably short"
Identifiers
  • 1-(2H-1,3-benzodioxol-5-yl)-N-ethylbutan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H19NO2
Molar mass221.300 g·mol−1
3D model (JSmol)
Melting point176 to 177 °C (349 to 351 °F)
  • O1c2ccc(cc2OC1)CC(NCC)CC
  • InChI=1S/C13H19NO2/c1-3-11(14-4-2)7-10-5-6-12-13(8-10)16-9-15-12/h5-6,8,11,14H,3-4,7,9H2,1-2H3
  • Key:IYZPKSQJPVUWRO-UHFFFAOYSA-N
  (verify)

EBDB, also known as 1,3-benzodioxolyl-N-ethylbutanamine, 3,4-methylenedioxy-α,N-diethylphenethylamine, or ethyl-J, is a psychoactive drug of the phenethylamine, phenylisobutylamine, and MDxx families. It is the N-ethyl analogue of BDB (J) and the α-ethyl analogue of MDEA.

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists EBDB's minimum dose as 90 mg orally and its duration as unknown. It produced few to no effects at the tested doses.

Chemistry

Synthesis

The chemical synthesis of EBDB has been described.

See also

References

  1. 1 2 3 4 5 6 7 Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. Ethyl-J Entry in PiHKAL
  2. ↑ Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
  3. ↑ Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.